EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Pharmacokinetic and bioequivalence study of two capecitabine tablets in Chinese patients with solid tumor cancer

Guangnan Zong, Jinlin Li, Xiushan Gong, Yuanyuan Liu, Xiuli Guo iD

Cancer Chemotherapy and Pharmacology · 2024

DOI: 10.1007/s00280-024-04652-w ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Cancer Chemotherapy and Pharmacology, 2024. Verfasst von Guangnan Zong und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicin…. Hauptthemen laut MEDLINE: Antimetabolites, Antineoplastic, Capecitabine, Neoplasms, Therapeutic Equivalency. Die Arbeit nennt 14 Literaturangaben. Gefördert von: Shandong New Times Pharmaceutical Co., Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Capecitabine (CAP) is one of the fluoropyrimidine deoxynucleoside carbamates, which can be converted to 5-fluorouracil (5-FU) by thymine deoxynucleoside phosphorylase (dThdPase) to exert antitumor effects. The purpose of this study is to compare the pharmacokinetics (PK), bioequivalence (BE), and safety of two CAP tablets in Chinese patients with solid tumor cancer. The results showed that the geometric mean ratios (GMRs) of Cmax, AUC0-t and AUC0-∞ of CAP T/R reagent were 90.26%, 95.27%, and 95.07, respectively. The values and 90% confidence intervals (CI) of AUC0-t, AUC0-∞, and Cmax all fall within the range of 80.00-125.00%. In addition, a total of 22 subjects in this study had 30 adverse events, with an incidence of 45.83%, and there were no serious adverse events and adverse events that led to withdrawal from the trial.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antimetabolites, AntineoplasticCapecitabineNeoplasmsTherapeutic EquivalencyAdultAgedFemaleHumansMaleMiddle AgedArea Under CurveChinaCross-Over StudiesEast Asian PeopleTablets

Stichwörter der Autor:innen

BioequivalenceCapecitabineSolid tumor cancer

Substanzen

Antimetabolites, AntineoplasticCapecitabineTablets

Autor:innen und Institutionen

  • Department of Pharmacology, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, No. 44 Wen Hua Xi Road, Jinan, 250012, People'…
  • Shandong New Times Pharmaceutical Co., Ltd, Linyi, People's Republic of China.
  • Clinical Trial Research Center, The First Affiliated Hospital of Bengbu Medical College, Bengbu, People's Republic of China.

ORCID-Profile: Xiuli Guo

Förderung

  • Shandong New Times Pharmaceutical Co., Ltd.

Zitieren

APA

Zong, G., Li, J., Gong, X., Liu, Y., & Guo, X. (2024). Pharmacokinetic and bioequivalence study of two capecitabine tablets in Chinese patients with solid tumor cancer. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-024-04652-w

Vancouver

Zong G, Li J, Gong X, Liu Y, Guo X. Pharmacokinetic and bioequivalence study of two capecitabine tablets in Chinese patients with solid tumor cancer. Cancer Chemotherapy and Pharmacology. 2024. doi:10.1007/s00280-024-04652-w

BibTeX
@article{Zong2024,
  author = {Zong, Guangnan and Li, Jinlin and Gong, Xiushan and Liu, Yuanyuan and Guo, Xiuli},
  title = {Pharmacokinetic and bioequivalence study of two capecitabine tablets in Chinese patients with solid tumor cancer},
  journal = {Cancer Chemotherapy and Pharmacology},
  year = {2024},
  doi = {10.1007/s00280-024-04652-w}
}
Kostenlos starten →